SEPTERNA
LIVE

Serial Number

97148591

Owner

Septerna, Inc.

Attorney

Shane Rumbaugh

Filing Date

Nov 30, 2021

Add to watchlist:

No watchlists yet
View on USPTO

SEPTERNA Trademark

Serial Number: 97148591

SEPTERNA is a trademark filed by Septerna, Inc. on November 30, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Septerna, Inc. (3 trademarks)

250 East Grand Ave., Suite 65
San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

November 30, 2021

Registration Date

Not Registered

Published for Opposition

April 25, 2023

Goods & Services

Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for scientific research use; chemical reagents for use in genetic research

Pharmaceutical preparations for modulating G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical preparations for use in neurology, endocrinology, metabolism, immunology, oncology, cardiovascular medicine, gastroenterology, pain, anesthesiology, dermatology, ophthalmology, psychiatry, pulmonology, urology, reproductive medicine, and orthopedics; pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, and that act on various GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; chemical and biochemical preparations and substances for medical purposes for treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; pharmaceutical preparations for targeting GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; biological preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for use in medical research

Custom manufacture of biochemical systems, namely, custom manufacture of systems for targeting G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; custom manufacturing for others, namely, manufacturing of pharmaceutical preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders

Providing a website featuring information about the treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders

Bio-technology and scientific services, namely, research, and production and development services relating to bio-technology and science, namely, G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical research and development; Scientific and technological services, namely, biological and bio-technology analysis services; scientific and medical laboratory services; biochemistry research services, namely, treating therapeutic targets through chemical and biochemical preparations

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 29, 2026 EXRA
SOU EXTENSION 5 GRANTED
May 29, 2026 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 11, 2026 AITU
SOU TEAS EXTENSION RECEIVED
Dec 11, 2025 EEXT
SOU EXTENSION 5 FILED
Dec 10, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 5, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 5, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 5, 2025 REAP
SOU EXTENSION 4 GRANTED
Jun 4, 2025 EX4G
SOU EXTENSION 4 FILED
Jun 4, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 4, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 3 GRANTED
Dec 13, 2024 EX3G
SOU EXTENSION 3 FILED
Dec 12, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 12, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 13, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jun 13, 2024 EX2G
SOU EXTENSION 2 FILED
Jun 13, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 13, 2024 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 16, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 16, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 16, 2024 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 20, 2023 EXRA
SOU EXTENSION 1 GRANTED
Dec 18, 2023 EX1G
SOU EXTENSION 1 FILED
Dec 18, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 18, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 20, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 25, 2023 NPUB
PUBLISHED FOR OPPOSITION
Apr 25, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 5, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 22, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 15, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 13, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 13, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 13, 2022 GNRN
NON-FINAL ACTION E-MAILED
Sep 13, 2022 GNRT
NON-FINAL ACTION WRITTEN
Sep 13, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 9, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 3, 2021 NWOS
NEW APPLICATION ENTERED
Dec 3, 2021 NWAP